Clinical Trials Browser

Withdrawn × Hodgkin Disease × Alemtuzumab × Clear all

NCT00129753 2018-11-08

Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease

Phase 2 Withdrawn

Hodgkin Disease, Lymphoma, Recurrence